Podcasts

Recent Episodes

February 2, 2026

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Eric Whitman, MD, medical director, oncology service line, Atlantic Health System; Vishal Patel, MD, FAAD, FACMS, associate professor, dermatology and medicine, GW School of Medicine & Health Sciences, director, Cutaneous Oncology Program, GW Cancer Center

January 31, 2026

Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMS

Komal Jhaveri, MD, FACP, breast medical oncologist, Memorial Sloan Kettering Cancer Center

January 31, 2026

ASCENT-07 Trial Propels Further Questions About the Role of Earlier-Line ADCs in HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

January 31, 2026

Expanded BTK Inhibitor Research Directs the Evolution of Pirtobrutinib Use in CLL: With Andrew Lipsky, MD

January 30, 2026

Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

January 30, 2026

Early, Reflex Biomarker Testing Is Critical to Optimizing NSCLC Treatment Decisions Across Disease Stages: With Adam Fox, MD, and Cynthia A. Schandl, MD, PhD

January 30, 2026

Subcutaneous Isatuximab via On-Body Injector Has Noninferior Efficacy vs IV Delivery in Myeloma: With Sikander Ailawadhi, MD; and Beth Faiman, CNP, PhD

January 30, 2026

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer

January 30, 2026

Multimodality in Oncology: Are We There Yet?

Tycel Phillips, MD, associate professor, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope

January 30, 2026

Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD

All series

All Podcasts

Catherine Shu, MD, Price Family Associate Professor of Medicine and the clinical director of the Thoracic Medical Oncology Service at the Columbia University Herbert Irving Comprehensive Cancer Center

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

ByCatherine Shu, MD

December 5th 2025

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

Gregory J. Tiesi, MD, FACS, FSSO, medical director, Hepatobiliary Surgery, Hackensack Meridian Jersey Shore University Medical Center; Anthony Scholer, MD, FACS, FSSO, surgical oncologist, hepatobiliary surgery, Hackensack Meridian Medical Group and Jersey Shore University Medical Center; Benjamin Jon Golas, MD, FACS, regional chief, Surgical Oncology, Hackensack Meridian Health’s Central Region, surgical director, Oncology Services, Jersey Shore University Medical Center, vice chair, Surgery, Jersey Shore University Medical Center Cancer Surgery, associate professor, surgery, Hackensack Meridian School of Medicine; Eric Pletcher, MD, surgeon, Complex General Surgical Oncology, Hackensack Meridian JFK University Medical Center

PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

ByGregory J. Tiesi, MD, FACS, FSSO,Anthony Scholer, MD, FACS, FSSO,Benjamin Jon Golas, MD, FACS,Eric Pletcher, MD

December 3rd 2025

Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.

Sarah Rutherford, MD, associate professor, clinical medicine, Division of Hematology/Oncology, Weill Cornell Medicine

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

BySarah Rutherford, MD

December 3rd 2025

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

Shubham Pant, MD, MBBS, professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, director, Clinical Research, professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

ByShubham Pant, MD, MBBS

December 2nd 2025

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Jacob Sands, MD, associate chief, Lowe Center for Thoracic Oncology, Oncology Medical Director, International Patient Center, Dana-Farber Cancer Institute, assistant professor, Harvard Medical School; Shailee Shah, MD, clinical assistant professor, neurology (MS/neuroimmunology) North,western University Feinberg School of Medicine

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

ByJacob Sands, MD,Shailee S. Shah, MD

December 1st 2025

Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.

Joshua Richter, MD, associate professor, medicine, The Tisch Cancer Institute; director, Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

ByJoshua Richter, MD

November 28th 2025

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Cassie Kline, MD, MAS, attending physician, director, Clinical Research, Department of Neuro-Oncology, Children's Hospital of Philadelphia

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

ByCassie Kline, MD, MAS

November 27th 2025

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

D. Ross Camidge, MD, PhD; Gideon Blumenthal, MD, vice president, Clinical Development Oncology, Merck

How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD

ByRoss Camidge, MD, PhD,Gideon Blumenthal, MD

November 26th 2025

Drs Camidge and Blumenthal discussed Dr Blumenthal's experience serving on both sides of the oncology regulatory divide.

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

ByDaniel Eidelberg Spratt, MD

November 25th 2025

Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

ByMarc S. Raab, MD

November 24th 2025

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Harry P. Erba, MD, PhD, professor, medicine, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, director, Leukemia Program, director, Phase I Development in Hematologic Malignancies; member, Duke Cancer Institute

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

ByHarry Erba, MD, PhD

November 21st 2025

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

ByJustin Taylor, MD

November 19th 2025

Justin Taylor, MD discusses how patients use AI to seek cancer information, its accuracy and limitations, and the implications for hematologic malignancy care.

Martha K. Terris, MD, FACS, department chair, professor, Department of Urology, Witherington Distinguished Chair in Urology, co-director, Cancer Center, Medical College of Georgia at Augusta University

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 18th 2025

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Benjamin P. Levy, MD Kamel Abou Hussein, MD Victoria Rizk, MD

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

ByBenjamin P. Levy, MD,Victoria Rizk, MD,Kamel Abou Hussein, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

ByBenjamin P. Levy, MD,Jonathan Lee, MD, MSc

November 14th 2025

Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.

Benjamin P. Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, associate professor, oncology, Johns Hopkins University School of Medicine; Scott T. Tagawa, MD, MS, FACP, FASCO, professor, medicine and urology, Weill Cornell Medicine, attending physician, NewYork-Presbyterian – Weill Cornell Medical Center

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

ByBenjamin P. Levy, MD,Scott T. Tagawa, MD

November 13th 2025

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Taymaa May, MD, MSc, director, Ovarian Cancer Surgery, Division of Surgical Oncology, Brigham and Women’s Hospital, associate professor, Harvard Medical School

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

ByUrsula A. Matulonis, MD,Taymaa May, MD, MSc

November 13th 2025

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

D. Ross Camidge, MD, PhD; Mark Socinski, MD, medical oncologist, executive medical director, AdventHealth Cancer Institute

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

ByRoss Camidge, MD, PhD,Mark A. Socinski, MD

November 12th 2025

Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory and the personal influences that helped him arrive where he is today.

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 11th 2025

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois

Urothelial ESMO 2025 Updates

BySamantha A. Armstrong, MD,Karine Tawagi, MD

November 11th 2025

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

Kevin Kalinsky, MD, MS, FASCO, professor, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; director, Glenn Family Breast Center, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Winship Cancer Institute

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ByKevin Kalinsky, MD, MS

November 7th 2025

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

ByStephen Liu, MD

November 6th 2025

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

ByHira Mian, MD

November 6th 2025

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, professor, medicine, Mayo Clinic; Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO nurse practitioner, Multiple Myeloma Program, Cleveland Clinic

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

BySikander Ailawadhi, MD,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Medical College of Georgia at Augusta University

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 4th 2025

Martha K. Terris, MD, FACS, discusses unique considerations for bladder cancer diagnosis and treatment among women

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Oncology Experts Dive Into Top Data From ESMO 2025

ByPaolo Tarantino, MD,Dana Chase, MD,Andrew W. Hahn, MD,Andrea Necchi, MD,Nicoletta Colombo, MD, PhD

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Ziad Hanhan, MD, thoracic surgeon, Hackensack Meridian Health, chairman, Surgery at Bayshore Medical Center, chief, Thoracic Surgery, Riverview Medical Center; Thomas Bauer, MD, chair, surgery, Jersey Shore University Medical Center and Hackensack Meridian Health School of Medicine; Rachel NeMoyer, MD, thoracic surgeon, Hackensack Meridian Health

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

ByZiad Hanhan, MD,Thomas Bauer, MD,Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

ByAmit Mehta, MD

October 29th 2025

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Armeen Mahvash, MD, professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center; assistant professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

ByArmeen Mahvash, MD

October 27th 2025

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Podcasts

Recent Episodes

All series

Pediatrics

Career GPS

Marvels in Medicine

Talking Tumors

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

CME Podcasts

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

Urothelial ESMO 2025 Updates

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

Oncology Experts Dive Into Top Data From ESMO 2025

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

Five Under 5: Top Oncology Videos for the Week of 1/25

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma